Trials / Completed
CompletedNCT02195700
Aim to Reduce Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 117 (actual)
- Sponsor
- Auspex Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SD-809 | SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period. |
| DRUG | Placebo | Placebo tablets taken twice daily for 12 weeks. |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2014-07-21
- Last updated
- 2021-11-09
- Results posted
- 2018-03-20
Locations
41 sites across 4 countries: United States, Czechia, Poland, Slovakia
Source: ClinicalTrials.gov record NCT02195700. Inclusion in this directory is not an endorsement.